AOU Consorziale Policlinico di Bari

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma	Active, not recruiting	Phase 2	2026-09-02		NCT06183489

Clinical trials